• Home
  • NEW DAY MEDICINE
  • 3 (77) 2025
  • 51 -3 (77) 2025 - Akhmadzhanova O.M., Alimkhodzhayeva L.T. - PROGNOSTIC SIGNIFICANCE OF TUMOR-INFILTRATING LYMPHOCYTES IN BREAST CANCER TUMOR-INFILTRATING LYMPHOCYTES IN BREAST CANCER

51 -3 (77) 2025 - Akhmadzhanova O.M., Alimkhodzhayeva L.T. - PROGNOSTIC SIGNIFICANCE OF TUMOR-INFILTRATING LYMPHOCYTES IN BREAST CANCER TUMOR-INFILTRATING LYMPHOCYTES IN BREAST CANCER

PROGNOSTIC SIGNIFICANCE OF TUMOR-INFILTRATING LYMPHOCYTES IN BREAST CANCER TUMOR-INFILTRATING LYMPHOCYTES IN BREAST CANCER

Akhmadzhanova O.M. - Republic of specialized oncology and radiology Scientific and practical medical center Uzbekistan

Alimkhodzhayeva L.T. - Republic of specialized oncology and radiology Scientific and practical medical center Uzbekistan

Resume

Tumor infiltrating lymphocytes (TILs) play an important role in mediating response to chemotherapy and improving clinical outcomes in all breast cancer subtypes. Triple-negative breast cancer (TN) most likely has tumors with >50% lymphocytic infiltration, termed lymphocyte-dominated breast cancer, and gains the greatest survival advantage for each 10% increase in TIL. Most HER2+ breast cancers have the same level of immune infiltrate as TN breast cancer, but the presence of TIL has not shown the same survival benefit. For breast cancer, HER2+ type 1 T cells, either increased TBET+ tumor infiltration or increased numbers of HER2-specific CD4+ type 1 T cells in peripheral blood are associated with better outcomes. Hormonal receptor-positive HER2-negative tumors tend to have the least immune infiltrate, but are the only subtype of breast cancer that has a poorer prognosis with an increased infiltrate of FOXP3 regulatory T cells. Notably, all breast cancer subtypes have tumors with low, moderate, or high TIL infiltrate. High TIL tumors may also have overexpression of PD-L1, which may be why TN breast cancer appears to show the strongest clinical response to immune checkpoint inhibitor therapy, but further research is needed. On the other hand, tumors with moderate or low levels of immune infiltrate prior to treatment may benefit from an intervention that can increase TIL, especially type 1 T cells. Examples of such interventions include certain types of cytotoxic chemotherapy, radiation therapy, or vaccine therapy. Thus, a systematic assessment of TILs and specific TIL populations can help both in determining prognosis and appropriate sequencing of breast cancer treatment.

Keywords: breast cancer, tumor infiltrating lymphocytes, CD8 T cells, FOXP3.

First page

271

Last page

279

For citation:Akhmadzhanova O.M., Alimkhodzhayeva L.T. - PROGNOSTIC SIGNIFICANCE OF TUMOR-INFILTRATING LYMPHOCYTES IN BREAST CANCER TUMOR-INFILTRATING LYMPHOCYTES IN BREAST CANCER//New Day in Medicine 3(77)2025 271-279 https://https://newdayworldmedicine.com/en/new_day_medicine/3-77-2025

List of References

  1. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27(35):5944-51. doi:10.1200/JCO.2008.19.6147.
  2. Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012;124(2):192-8. doi:10.1016/j.ygyno.2011.09.039.
  3. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008; 26(27):4410-7. doi: 10.1200/JCO.2007.15.0284.
  4. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al. Tumor- associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010; 28(1):105-13. doi:10.1200/JCO.2009.23.7370.
  5. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin- based chemotherapy: BIG 02-98. J Clin Oncol. 2013; 31(7):860-7. doi: 10.1200/JCO.2011.41.0902.
  6. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015; 15(7):405-14. doi:10.1038/nri3845.
  7. Tan AH, Goh SY, Wong SC, Lam KP. T helper cell-specific regulation of inducible costimulator expression via distinct mechanisms mediated byT-bet and GATA-3. J Biol Chem. 2008; 283(1):128-36. doi:10.1074/jbc.M707693200.
  8. Hussein MR, Hassan HI. Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations. J Clin Pathol. 2006; 59 (9):972-7. doi:10.1136/jcp.2005.031252.
  9. Thompson E, Taube JM, Elwood H, Sharma R, Meeker A, Warzecha HN, et al. The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol. 2016; 29(3):249-58. doi:10.1038/modpathol.2015.158.
  10. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006; 24(34):5373-80. doi:10.1200/JCO.2006.05.9584.
  11. Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci USA. 2012;109(8):2802-7. doi:10.1073/pnas.1108781108.
  12. Marquez JP, Stanton SE, Disis ML. The antigenic repertoire of premalignant and high-risk lesions. Cancer Prev Res (Phila). 2015;8(4):266-70. doi:10.1158/1940-6207.capr-14-0314.
  13. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011; 29(15):1949-55. doi:10.1200/JCO.2010.30.5037.
  14. Baker K, Lachapelle J, Zlobec I, Bismar TA, Terracciano L, Foulkes WD. Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology. 2011; 58(7):1107-16. doi:10.1111/j.1365-2559.2011.03846.x.
  15. Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012; 14(2):R48. doi:10.1186/bcr3148.
  16. Oda N, Shimazu K, Naoi Y, Morimoto K, Shimomura A, Shimoda M, et al. Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients. Breast Cancer Res Treat. 2012; 136(1):107-16. doi:10.1007/s10549-012-2245-8.
  17. Mulligan AM, Pinnaduwage D, Tchatchou S, Bull SB, Andrulis IL. Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer. Cancer Immunol Res. 2016; 4(1):41-8. doi:10.1158/2326-6066.CIR-15-0051.
  18. Adams S, Gray RJ, Demaria S, Goldstein LJ, Perez EA, Shulman LN, et al. Prognostic Value of Tumor-Infiltrating Lymphocytes (TILs) in Triple Negative Breast Cancers (TNBC) from two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014; 32:2959-66.
  19. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes is prognostic and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014. doi:10.1093/annonc/mdu112.
  20. Dieci MV, Mathieu MC, Guarneri V, Conte P, Delaloge S, Andre F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol. 2015; 26(8):1698-704. doi:10.1093/annonc/mdv239.

    file

    download